Introduction: Primary retroperitoneal mature cystic teratomas (PRPMCT) are uncommon in adults. They typically occur in infants under six months old and young females. So far, some limited case reports have been documented in the literature. This case report presents a rare case of an adult patient with PRPMCT aged over 30 years. Case Presentation: The patient was a 34-year-old female with PRPMCT in the site of the left adrenal gland and abdominal discomfort. Computed tomography (CT) scan revealed a 66 mm hypodense lesion with fat attenuation and calcification in the left retroperitoneum. Laparotomy with resection of the retroperitoneal (RP) lesion was done. Gross examination showed a solid multicystic mass measuring 8x6.5x6 cm. Histopathologic examination revealed a neoplastic tissue composed of mature osseous and cartilaginous tissue associated with stratified squamous epithelium and lumens lined by ciliated columnar epithelium, and the diagnosis was mature cystic teratoma. The patient had an uncomplicated postoperative course without recurrence after seven months of follow-up. Conclusions: PRPMCT in adults is extremely rare. RP metastasis of primary gonadal teratoma and non-functioning adrenal tumors should be excluded first. Due to the diagnostic difficulty of posterior peritoneal teratoma with radiological imaging and its risk of malignancy, surgical resection would be the most effective diagnostic and therapeutic option. Complete resection of the mass is important to judge the existence of immature and solid components that require a long-time follow-up because of the increased risk of malignancy.
Background: Bladder cancer is the second most common urologic malignancy. Transurethral resection (TUR) is the standard initial treatment for non-muscle-invasive bladder cancer (NMIBC). The high prevalence of residual tumor in some patients has necessitated repeat TUR (re-TUR). Previous studies have shown the quality of primary resection to impact re-TUR outcomes, but the role of tumor biology remains unclear. Objectives: This study aimed to evaluate the impact of tumor biology on re-TUR results in primary (non-recurrent) patients with superficial bladder tumors. Methods: We studied a cohort of consecutive primary patients with superficial bladder cancer undergoing resection and routine re-TUR between March 2018 and February 2019 at our unit. Patients with TaG1 or T2 on primary pathologic report, deliberately incomplete initial resection, or absence of detrusor muscle on the initial specimen were excluded from the study. Re-TUR was performed in the sixth week. All procedures were performed by the same surgeon. The patients were divided into three groups according to the European Organization for Research and Treatment of Cancer (EORTC) risk scoring system and compared for recurrence of NMIBC. Results: Of 58 primary patients, 16 were classified as low-risk, 32 as intermediate-risk, and 10 as high-risk. The mean age of subjects was 62.1 years. Residual tumor was detected on re-TUR in 19 (32.7%) cases. Also, 3 (5.2%) cases entailed stage progression to pT2, all of whom belonged to the high-risk group. Residual tumor rate was 0%, 40.6%, and 60% in the low-, intermediate-, and high-risk groups, respectively. In addition, 13 patients had macroscopic residual. Conclusions: Despite the modest study size, our results suggest that tumor biology might have an impact on residual tumor characteristics, and the EORTC scoring system may help to predict the risk of progression and residual tumor rate on re-TUR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.